Interpace Diagnostics buys 2 microRNA tests from Asuragen

08/15/2014 | GenomeWeb Daily News (free registration)

Interpace Diagnostics, a unit of PDI, has agreed to acquire Asuragen's miRInform Pancreas and Thyroid cancer tests for $8 million. The deal, which also covers a tissue sample biobank and intellectual property associated with the assays and other thyroid cancer tests under development, should allow Interpace to make inroads in the molecular diagnostics arena.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC